Teleflex sells Acute Care, Interventional Urology, and OEM businesses for $2.03B; authorizes $1B buyback

TELEFLEX INC

Total cash consideration $2.03B: OEM business to Montagu/Kohlberg for $1.5B; Acute Care and Interventional Urology to Intersurgical for $530M.
Net after-tax proceeds expected ~$1.8B; primarily used for share repurchases and debt reduction.
Board authorized $1B share repurchase program, funded from transaction proceeds.
Transactions expected to close in H2 2026, subject to regulatory approvals and customary conditions.
Teleflex will focus on remaining core businesses: Vascular Access, Interventional, and Surgical, targeting mid-single-digit growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.